Welcome to our dedicated page for Longboard Pharmaceuticals news (Ticker: LBPH), a resource for investors and traders seeking the latest updates and insights on Longboard Pharmaceuticals stock.
Longboard Pharmaceuticals, Inc. (symbol: LBPH) is a clinical-stage biopharmaceutical company dedicated to developing novel, transformative medicines aimed at treating rare neurological diseases. With a focus on optimized pharmacology and pharmacokinetics, Longboard's proprietary pipeline features multiple potentially first- or best-in-class programs that hold broad clinical utility.
The company is currently evaluating several promising drug candidates:
- LP352: A next-generation 5-HT2C agonist. This oral, centrally acting superagonist aims to treat developmental and epileptic encephalopathies (DEEs) while minimizing impact on 5-HT2B and 5-HT2A receptor subtypes.
- LP143: A centrally acting, full agonist of the cannabinoid type 2 receptor (CB2). This candidate is being developed for its potential therapeutic effects in neurological conditions.
- LP659: A highly selective, next-generation S1P receptor modulator with central action, being evaluated for its efficacy in treating neurological diseases.
Longboard Pharmaceuticals is driven by a team committed to delivering transformational medicines. The company’s focus on GPCR-targeted therapies aims to offer precise treatment options tailored to specific receptor subtypes, thereby enhancing efficacy and safety profiles. By advancing its clinical programs through rigorous scientific research and development, Longboard strives to address unmet medical needs and improve the quality of life for patients with rare neurological conditions.
Stay informed about the latest developments and updates from Longboard Pharmaceuticals, Inc. as they continue to make strides in the biopharmaceutical industry.
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) announces the presentation of Phase 1b/2a clinical data from the PACIFIC Study on bexicaserin at the AAN Annual Meeting and EILAT XVII. The study evaluates the drug in patients with DEEs, showcasing its efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.39%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) granted inducement awards to three new employees, offering 99,500 non-qualified stock options. The options have an exercise price of $21.60 per share, vesting over time. This move aims to attract and retain top talent in the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.39%
Tags
-
News
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. reports positive topline data from the Phase 1b/2a PACIFIC Study for bexicaserin (LP352) in participants with DEEs, showcasing significant seizure reductions. The company plans to initiate a global Phase 3 program by YE 2024 and expects to present PACIFIC data at medical meetings in Q2 2024. Additionally, the Phase 1 SAD study for LP659 is on track, with financial results indicating a strong cash position after a successful public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.05%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) granted inducement awards to four new employees in the form of non-qualified stock options. The options allow the purchase of 184,000 shares of Common Stock at an exercise price of $22.18 per share. The options vest over time, with 25% becoming exercisable after one year and the remaining 75% in monthly installments over 36 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) granted inducement awards to five new employees in the form of non-qualified stock options to purchase 145,475 shares of its common stock. The options were granted on January 31, 2024, with an exercise price of $21.24 per share. Vesting is structured with 25% on the one-year anniversary of employment start date and the remaining 75% in 36 monthly installments, contingent on continued employment. The grants were approved by the Compensation Committee and are in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) announced that its senior leadership team will present at two investor conferences in February. The company will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024, and the Oppenheimer 34th Annual Healthcare Life Sciences Virtual Conference on February 14, 2024. The presentations will be available via live webcasts on the company's website and will be archived for at least 30 days after the events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (LBPH) announced the closing of its underwritten public offering of 11,500,000 shares of its voting common stock, grossing approximately $241.5 million. The offering was made pursuant to two shelf registration statements on Form S-3, including base prospectuses, previously filed with the SEC. Cantor and Citigroup acted as joint lead book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.77%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company (Nasdaq: LBPH), announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at $21.00 per share. The gross proceeds are expected to be $210.0 million. The offering is expected to close on January 8, 2024. Cantor and Citigroup are acting as joint lead book-running managers for the offering. The offering is being made pursuant to two shelf registration statements on Form S-3, including base prospectuses, previously filed with the SEC and declared effective on October 11, 2022 and August 11, 2023, respectively, as well as a related registration statement on Form S-3MEF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.94%
Tags
-
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) has announced a proposed underwritten public offering to issue and sell $150 million of shares of its voting common stock, with a 30-day option to purchase up to an additional approximately $22.5 million of shares. Cantor and Citigroup are acting as joint lead book-running managers for the offering, with Wedbush PacGrow and H.C. Wainwright & Co. as lead managers. The offering is being made pursuant to two shelf registration statements on Form S-3, declared effective on October 11, 2022 and August 11, 2023. A preliminary prospectus supplement will be filed with the SEC and will be available for free on the SEC’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.76%
Tags
Rhea-AI Summary
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The study showed a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population, with favorable safety and tolerability results. Longboard is rapidly moving forward with preparations for its global Phase 3 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
316.25%
Tags
FAQ
What is the current stock price of Longboard Pharmaceuticals (LBPH)?
The current stock price of Longboard Pharmaceuticals (LBPH) is $59.98 as of November 29, 2024.
What is the market cap of Longboard Pharmaceuticals (LBPH)?
The market cap of Longboard Pharmaceuticals (LBPH) is approximately 2.3B.
What does Longboard Pharmaceuticals, Inc. specialize in?
Longboard Pharmaceuticals specializes in developing novel, transformative medicines for rare neurological diseases, focusing on optimized pharmacology and pharmacokinetics.
What are the key drug candidates in Longboard's pipeline?
Key drug candidates include LP352, a 5-HT2C agonist for DEEs, LP143, a CB2 receptor full agonist, and LP659, a selective S1P receptor modulator.
What is LP352?
LP352 is a next-generation 5-HT2C agonist in development for the potential treatment of developmental and epileptic encephalopathies (DEEs).
What is unique about LP143?
LP143 is a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), being developed for its therapeutic potential in neurological conditions.
What is the focus of Longboard Pharmaceuticals' research?
The focus is on developing centrally acting product candidates that are selective for specific G protein-coupled receptors (GPCRs) to treat neurological diseases.
Who can benefit from Longboard's medicines?
Patients with rare neurological diseases and conditions, such as developmental and epileptic encephalopathies, may benefit from Longboard's novel treatments.
How does Longboard ensure the safety of its treatments?
Longboard employs rigorous scientific research and development to ensure its treatments have optimized pharmacology and pharmacokinetics, aiming for high efficacy and safety.
Is Longboard Pharmaceuticals a publicly traded company?
Yes, Longboard Pharmaceuticals, Inc. is publicly traded under the stock symbol LBPH.
Where can I find the latest news about Longboard Pharmaceuticals?
You can stay informed about the latest developments and updates from Longboard Pharmaceuticals, Inc. on their official website or trusted financial news platforms like StockTitan.
What are the potential applications of LP659?
LP659 is a next-generation, highly selective S1P receptor modulator being evaluated for its potential applications in treating neurological diseases.
Longboard Pharmaceuticals, Inc.
Nasdaq:LBPH
LBPH Rankings
LBPH Stock Data
2.34B
33.87M
1.2%
121.42%
4.94%
Biotechnology
Pharmaceutical Preparations
United States of America
LA JOLLA